The Pharma Data
JUNE 25, 2025
This designation represents a significant regulatory milestone for Sanofi and further underscores the company’s expanding efforts to address rare and serious immune-mediated disorders. This form of rejection can occur early or late after transplantation and is notoriously difficult to treat.
Broad Institute
MAY 21, 2025
He showed that these synthetic CAR T cells could launch an immune response when they encountered the corresponding tumor protein, called CD19. That ability to stick around, which is critical for attacking cancer over time, was another turning point. In some cases, patients treated with the new therapy remained cancer-free for years.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JUNE 15, 2025
Food and Drug Administration (FDA)-approved gene therapy for the treatment of Duchenne muscular dystrophy (DMD). Sarepta’s team is exploring adding sirolimus — a well-established immunosuppressive medication — to the regimen in a way that might enable a greater degree of control over the patient’s immune response.
Codon
JULY 28, 2025
Casgevy , the first FDA-approved CRISPR-based therapy, is also an ex vivo gene therapy; it aims to cure sickle cell disease by editing a patient’s blood-producing stem cells so they generate functional fetal hemoglobin, then returning these corrected cells to the bloodstream. This changed with the discovery of AAVs.
Codon
NOVEMBER 3, 2024
If present before vaccination, memory immune cells primed to destroy the environmental relatives might cross-react with and neutralize the BCG strain before it has a chance to set up an immune response against itself and M. Food and Drug Administration (FDA)-approved drug library, some of which inhibit E.
Codon
JUNE 5, 2025
The treatment, now known as Casgevy, became the first CRISPR-based therapy to gain FDA approval, in 2023. The core of the CRISPR immune response is a guide RNA (gRNA) that binds to a CRISPR-associated (Cas) protein. Collectively, these repeat-protospacer regions are known as CRISPR arrays.
The Pharma Data
OCTOBER 26, 2020
EYSUVIS is the first FDA-approved corticosteroid specifically for dry eye disease treatment. The corticosteroid then works to relieve swelling, redness and itching by targeting the immune response that drives dry eye disease flares. . Over-the-counter treatments fail due to the body’s natural protective system.
Expert insights. Personalized for you.
Let's personalize your content